Prevalence of Drug-Resistant HIV-1 in Rural Areas of Hubei Province in the People's Republic of China

被引:20
作者
Luo, Minqi [2 ,3 ,4 ]
Liu, Huan [2 ,3 ]
Zhuang, Ke [2 ,3 ]
Liu, Li [1 ]
Su, Bo [2 ,3 ]
Yang, Rongrong [4 ]
Tien, Po [2 ,3 ]
Zhang, Linqi [5 ]
Gui, Xien [4 ]
Chen, Zhiwei [1 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, AIDS Inst, Hong Kong, Hong Kong, Peoples R China
[2] Wuhan Univ, Coll Life Sci, State Key Lab Virol, AIDS Center, Wuhan, Hubei, Peoples R China
[3] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Modern Virol Res Ctr, Wuhan, Hubei, Peoples R China
[4] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Wuhan, Peoples R China
[5] Chinese Acad Med Sci, AIDS Res Ctr, Peking Union Med Coll, Beijing 100037, Peoples R China
基金
美国国家卫生研究院;
关键词
China; drug resistance; HAART; HIV-1; subtype B'; ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; MULTIDRUG-RESISTANT; INFECTED PATIENTS; INDIVIDUALS; PATTERNS; CHILDREN; PROTEASE; VIRUS; SURVEILLANCE;
D O I
10.1097/QAI.0b013e31818ffcdc
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the prevalence of drug-resistant HIV-1 and the efficacy of first-line highly active antiretroviral therapy (HAART) regimens consisted of generic nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor among 339 study subjects in rural areas of Hubei province, China. Methods: Two cross-sectional studies were conducted to investigate 150 HAART-naive (99 received subsequent therapy) between 2003 and 2005 and 288 HAART-experienced patients mainly between 2005 and 2006. Patients' CD4(+) T-cell count and viral load were determined. HIV-1 pol gene fragments were amplified from patients' plasma by reverse transcriptase-polymerase chain reaction, subsequently sequenced and analyzed. Results: About 83.5% of the patients were from rural villages. They were dominantly infected with subtype B' HIV-1 (96.7%) through paid blood donation (64.6%) and related blood transfusion (28.3%). We found that there was a steady increase of CD4 count over time among treated patients without detectable viral load (186/288, 64.6%). There was, however, an increasing prevalence of nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant mutations among patients with detected viremia (102/288, 35.4%) after treatment for 3-6 (24.3%), 9-12 (57.1%), and 20-24 (63.3%) months, respectively. The increasing rates were associated with significant CD4 count drop and viral load increase. Some patients also developed multidrug-resistant mutants. Conclusions: We report the first HIV-1 drug resistance study after 2 years on HAART among Chinese patients living in rural villages. Our data suggest that a significant portion of patients are failing first-line regimens with a trend of AIDS progression. It is therefore necessary to maximize the drug adherence and to make affordable second-line HAART regimens available immediately Our results have implications for implementing HAART in underresourced developing country settings.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 37 条
  • [1] Antinori A, 2006, ANTIVIR THER, V11, P233
  • [2] Care of HIV-infected patients in China
    Cao, YZ
    Lu, HZ
    [J]. CELL RESEARCH, 2005, 15 (11-12) : 883 - 890
  • [3] Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
    Cingolani, A
    Antinori, A
    Rizzo, MG
    Murri, R
    Ammassari, A
    Baldini, F
    Di Giambenedetto, S
    Cauda, R
    De Luca, A
    [J]. AIDS, 2002, 16 (03) : 369 - 379
  • [4] Clotet B, 2004, AIDS REV, V6, P123
  • [5] Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine
    Conway, B
    Wainberg, MA
    Hall, D
    Harris, M
    Reiss, P
    Cooper, D
    Vella, S
    Curry, R
    Robinson, P
    Lange, JMA
    Montaner, JSG
    [J]. AIDS, 2001, 15 (10) : 1269 - 1274
  • [6] Delaugerre C, 2004, ANTIVIR THER, V9, P415
  • [7] The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis
    Dunn, Linda A.
    Andrews, Katherine T.
    McCarthy, James S.
    Wright, Janelle M.
    Skinner-Adams, Tina S.
    Upcroft, Peter
    Upcroft, Jacqueline A.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (01) : 98 - 102
  • [8] To stop or not to stop: That is the question, but what is the answer?
    Hogg, RS
    Havlir, D
    Miller, V
    Montaner, JSG
    [J]. AIDS, 2002, 16 (05) : 787 - 789
  • [9] Johnson Victoria A, 2007, Top HIV Med, V15, P119
  • [10] Johnson Victoria A, 2006, Top HIV Med, V14, P125